Janio Szklaruk
UT MD Anderson Cancer Center, USA
Title: Hepatocellular carcinoma 2017: MR and MSCT imaging
Biography
Biography: Janio Szklaruk
Abstract
Worldwide, hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related death with over 500,000 new cases occurring per year. Some of the risk factors associated with HCC include hepatitis B and C, cirrhosis, alcoholic liver disease and aflatoxin exposure. Multislice-computed tomography (MSCT) and magnetic resonance imaging (MRI) are commonly used in the diagnosis, staging, and surveillance of these patients. The purpose of this presentation is to demonstrate a step-wise approach to the radiological evaluation of patients suspected with HCC. The presentation will discuss the importance of the optimum imaging protocol and the common. The new LIRADS criteria for the diagnosis of HCC and the application of Gd-EOB-DTPA to the management of HCC will be presented. Relevant imaging information to provide appropriate staging for HCC will be presented. Following the treatment of HCC, the detection of recurrent disease also depends on imaging findings. The imaging patterns that distinguish post-treatment changes versus recurrent disease will be presented. The goals of this presentation are for the participants to (i) to learn the importance of optimum imaging protocols, (ii) to become familiar with the imaging features of HCC, (iii) to recognize the imaging patterns of recurrence following treatment.